Join

Compare · ECOR vs TMDX

ECOR vs TMDX

Side-by-side comparison of electroCore Inc. (ECOR) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ECOR and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • TMDX is the larger of the two at $3.25B, about 38.0x ECOR ($85.4M).
  • Over the past year, ECOR is up 73.6% and TMDX is down 18.7% - ECOR leads by 92.3 points.
  • ECOR has been more active in the news (7 items in the past 4 weeks vs 5 for TMDX).
  • TMDX has more recent analyst coverage (19 ratings vs 2 for ECOR).
PerformanceECOR+73.57%TMDX-18.71%
2025-08-26+0.00%2026-08-25
MetricECORTMDX
Company
electroCore Inc.
TransMedics Group Inc.
Price
$9.39-2.59%
$93.68+0.10%
Market cap
$85.4M
$3.25B
1M return
+52.81%
+25.93%
1Y return
+73.57%
-18.71%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NASDAQ
IPO
2018
2019
News (4w)
7
5
Recent ratings
2
19
ECOR

electroCore Inc.

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.

TMDX

TransMedics Group Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Latest ECOR

Latest TMDX